Strategic Cooperation Agreement Signed Between Tigermed and Haihe Pharmaceutical
September 14, 2018
An agreement on long-term strategic cooperaiton was signed between Hangzhou Tigermed Consulting Co., Ltd. (“Tigermed”) and Shanghai HaiHe Biopharma Co., Ltd. (“Haihe Biopharma”) on Sep 9, 2018. Tigermed and Haihe Biopharma will engage in strategic cooperation in clinical research of innovative drugs and, by giving full play to their respective advantages, achieve win-win cooperation in the field. Tigermed will provide clinical tests, data management and statistics, medical affairs, pharmacovigilance, quality control, personnel training, medical imaging, PK sample testing, central laboratory testing, logistics of laboratory test samples as well as investigational drugs, among other services. The two sides has reached consensus on matters with regard to the cooperation. Dr. Xiaoping Ye, Tigermed’s Chairman, and Dr. Ruiping Dong, CEO of Haihe Biopharma, signed the agreement on long-term cooperation in the field of innovative drug research and development.
With the mission to “Be inclusive, Harmonious and Win-win, Innovation-centered and Benefit-creating to Mankind”, Shanghai HaiHe Biopharma Co., Ltd. is a bio-pharmaceutical company focused on discovery, development and commercialization of innovative anti-cancer drugs. It adheres to independent innovation and, through establishing strategic partnership with Shanghai Institute of Materia Medica, CAS, seeks international development of originator drugs in China.
ABOUT Haihe Pharmaceutical
Shanghai Haihe Pharmaceutical Co., Ltd. amalgamated with RMX Biopharma in March 2018, resulting in the founding of Shanghai Haihe Biopharma Co., Ltd. The company has a management team led by CAE Academician(s) and consisting of members from the National Recruitment Program of Global Experts, which boasts rich experience and attaches importance to innovation. A technical platform for preclinical evaluation of new drugs and a clinical research system characterized by full-range functions, state-of-the-art technology, standard operation and compliance to international calibers have been established, covering unit systems from drug synthesis, quality study, preparation research, pharmacologic and pharmacodynamic evaluation to biomarker discovery and confirmation, medical strategic planning and clinical research, among others, and having built up a new drug R&D system and product pipeline with superposed advantages and international competitive edges. Presently the company has 10 compounds at the clinical stage and 5 at the preclinical stage.
Hangzhou Tigermed Consulting Co., Ltd（stock symbol: 300347） is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 32 subsidiaries, 95 offices across China and 12 overseas offices in Hong Kong China, Taiwan China, USA, Switzerland, Korea, Australia, Japan, Malaysia, Singapore , India and Romania with over 4100 full time staffs. Tigermed has serviced more than 600 local and global clients in the conduct of over 1060 clinical trials. Tigermed is recognized as “The Innovative CRO” in China，owning to our involvement of over 150 innovative drugs.